<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors></authors><secondary-authors><author><style face="normal" font="default" size="100%">Richter, Dominique</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Aliskiren-Based Therapy Controls Blood Pressure Regardless of Plasma Renin Activity</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">7-7</style></pages><abstract><style  face="normal" font="default" size="100%">Although aliskiren is established as an effective antihypertensive agent, it is not known whether its BP-lowering effects are dependent on baseline plasma renin activity (PRA) levels. The current prospective, open-label trial was defined to evaluate the ability of aliskiren to control BP alone and in combination with other antihypertensive medications in patients with various baseline PRA levels.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>